Morgan Stanley
PMCB icon

Morgan Stanley’s PharmaCyte Biotech PMCB Stock Holding History

Morgan Stanley’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Buy
2
+1
+100% +$1 ﹤0.01% 8390
2026
Q1 		$1 Sell
1
-1
-50% -$1 ﹤0.01% 8281
2025
Q4 		$2 Sell
2
-7
-78% -$6 ﹤0.01% 8179
2025
Q3 		$10 Buy
9
+8
+800% +$8 ﹤0.01% 8098
2025
Q2 		$1 Hold
1
– – ﹤0.01% 8085
2025
Q1 		$2 Sell
1
-1
-50% -$2 ﹤0.01% 8069
2024
Q4 		$4 Hold
2
– – ﹤0.01% 7936
2024
Q3 		$5 Sell
2
-1
-33% -$2 ﹤0.01% 7887
2024
Q2 		$7 Hold
3
– – ﹤0.01% 7798
2024
Q1 		$9 Sell
3
-5
-63% -$11 ﹤0.01% 7776
2023
Q4 		$18 Buy
8
+5
+167% +$11 ﹤0.01% 7761
2023
Q3 		$8 Sell
3
-18
-86% -$46 ﹤0.01% 7569
2023
Q2 		$60 Sell
21
-10
-32% -$30 ﹤0.01% 7529
2023
Q1 		$90 Sell
31
-24
-44% -$71 ﹤0.01% 7579
2022
Q4 		$161 Buy
55
+24
+77% +$69 ﹤0.01% 7662
2022
Q3 		$0 Sell
31
-2,495
-99% -$6.31K ﹤0.01% 7830
2022
Q2 		$6K Sell
2,526
-59,343
-96% -$130K ﹤0.01% 7366
2022
Q1 		$142K Sell
61,869
-6,264
-9% -$13.9K ﹤0.01% 6110
2021
Q4 		$170K Buy
68,133
+66,784
+4,951% +$184K ﹤0.01% 6145
2021
Q3 		$4K Buy
+1,349
New +$4.74K ﹤0.01% 7550

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Morgan Stanley's PMCB Position: Q2 2026 in Review

Morgan Stanley increased its PharmaCyte Biotech (PMCB) stake by 100% in Q2 2026, buying an estimated $1 and bringing the position to 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #8390.

Morgan Stanley first reported a position in PMCB in Q3 2021 and has held it in 20 quarters since. The position peaked at $170K in Q4 2021. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • Morgan Stanley held 2 shares of PharmaCyte Biotech worth $2 as of Q2 2026.
  • Morgan Stanley bought 1 PharmaCyte Biotech share in Q2 2026, an estimated $1.
  • PharmaCyte Biotech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8390 holding.
  • Morgan Stanley first reported a position in PharmaCyte Biotech in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's PharmaCyte Biotech position peaked at $170K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.